Nothing Special   »   [go: up one dir, main page]

RU2001114528A - A receptor body that specifically binds a TIE-2 ligand, an isolated nucleic acid molecule, a plasmid, a pharmaceutical composition, a method for preventing or attenuating neovascularization in a mammal - Google Patents

A receptor body that specifically binds a TIE-2 ligand, an isolated nucleic acid molecule, a plasmid, a pharmaceutical composition, a method for preventing or attenuating neovascularization in a mammal

Info

Publication number
RU2001114528A
RU2001114528A RU2001114528/13A RU2001114528A RU2001114528A RU 2001114528 A RU2001114528 A RU 2001114528A RU 2001114528/13 A RU2001114528/13 A RU 2001114528/13A RU 2001114528 A RU2001114528 A RU 2001114528A RU 2001114528 A RU2001114528 A RU 2001114528A
Authority
RU
Russia
Prior art keywords
receptor body
tie
pharmaceutical composition
mammal
ligand
Prior art date
Application number
RU2001114528/13A
Other languages
Russian (ru)
Other versions
RU2216593C2 (en
Inventor
Сэмюэль ДЭВИС
Джоан БРУНО
Митчелл ГОЛДФАРБ
Томас Х. ОЛДРИЧ
Питер С. МЭЙСОНПЬЕР
Чеслав РАДЗИЕВСКИ
Памела Ф. ДЖОНС
Джордж Д. Янкопулос
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/319,932 external-priority patent/US5643755A/en
Priority claimed from US08/418,595 external-priority patent/US5814464A/en
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of RU2001114528A publication Critical patent/RU2001114528A/en
Application granted granted Critical
Publication of RU2216593C2 publication Critical patent/RU2216593C2/en

Links

Claims (5)

1. Рецепторное тело, которое специфически связывает TIE-2 лиганд, имеющий аминокислотную последовательность, представленную на фиг.4, фиг.5 или фиг.6.1. A receptor body that specifically binds a TIE-2 ligand having the amino acid sequence shown in FIG. 4, FIG. 5 or FIG. 6. 2. Выделенная молекула нуклеиновой кислоты, кодирующая рецепторное тело по п.1.2. The selected nucleic acid molecule encoding the receptor body according to claim 1. 3. Плазмида, обозначенная как vTIE-2 рецепторное тело (АТСС депозит VR2484).3. Plasmid designated as vTIE-2 receptor body (ATCC deposit VR2484). 4. Фармацевтическая композиция, включающая эффективное количество TIE-2 рецепторного тела по п.1, и фармацевтически приемлемый носитель для предотвращения или ослабления нейроваскуляризации у млекопитающих.4. A pharmaceutical composition comprising an effective amount of TIE-2 receptor body according to claim 1, and a pharmaceutically acceptable carrier for preventing or attenuating neurovascularization in mammals. 5. Способ лечения человека или животного, включающий введение млекопитающему фармацевтической композиции по п.4.5. A method of treating a human or animal, comprising administering to the mammal a pharmaceutical composition according to claim 4.
RU2001114528A 1994-10-07 1995-10-06 Receptor body specifically binding ligand tie-2, isolated nucleic acid molecule, plasmid, pharmaceutical composition and method for prevention or attenuation of neovascularization in mammals RU2216593C2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US08/319,932 1994-10-07
US08/319,932 US5643755A (en) 1994-10-07 1994-10-07 Nucleic acid encoding tie-2 ligand
US08/330,261 1994-10-27
US08/418,595 1995-04-06
US08/348,492 1995-04-06
US08/373,579 1995-04-06
US08/353,503 1995-04-06
US08/418,595 US5814464A (en) 1994-10-07 1995-04-06 Nucleic acids encoding TIE-2 ligand-2

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU97107471/13A Division RU2232812C2 (en) 1994-10-07 1995-10-06 Isolated nucleic acid molecule encoding ligand tie-2, ligand tie-2 and method for preparing, plasmid (variants), antibody, conjugate, ligand body, pharmaceutical composition, method for stimulating neo-vascularization, method for cell maintenance, method for identifying tie-2 receptor antagonist

Publications (2)

Publication Number Publication Date
RU2001114528A true RU2001114528A (en) 2003-10-20
RU2216593C2 RU2216593C2 (en) 2003-11-20

Family

ID=32033307

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001114528A RU2216593C2 (en) 1994-10-07 1995-10-06 Receptor body specifically binding ligand tie-2, isolated nucleic acid molecule, plasmid, pharmaceutical composition and method for prevention or attenuation of neovascularization in mammals

Country Status (1)

Country Link
RU (1) RU2216593C2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1742966B1 (en) * 2004-04-22 2013-11-27 Agensys, Inc. Antibodies and molecules derived therefrom that bind to steap-1 proteins

Similar Documents

Publication Publication Date Title
RU96115200A (en) 2,4-DISULFOFENYLBUTILNITRON, ITS SALT AND THEIR APPLICATION AS PHARMACEUTICAL SPIN TRAPS
RU96116984A (en) IMMUNITY MULTI-MONOCLONAL ANTIBODIES
CA2146973A1 (en) Uses of tgf-.beta. receptor fragment as a therapeutic agent
IL112664A0 (en) 4-amino derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
DE69232263D1 (en) RADICAL COLLECTOR ("SPIN TRAPS") FOR THE TREATMENT OF DISEASES RELATED TO THE OXIDATION OF LIPIDS AND PROTEINS
HUP0001136A2 (en) Remedies for lymphocytic tumors
CA2010321A1 (en) Lymphocyte-associated cell surface protein
OA09374A (en) "New 1, 2, 3, 4, 5, 6-hexahydroazepino [4,5-b] indoles and 1, 2, 3, 4-tetrahydro B carbolines, their preparation processes and pharmaceutical compositions which contain them".
EP1003494A4 (en) (d)-METHADONE, A NONOPIOID ANALGESIC
CA2108963A1 (en) Compositions and Methods for Therapy and Prevention of Cancer, Aids and Anemia
EP0981360A4 (en) Method for preventing gastritis using amylin or amylin agonists
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
EA199800717A1 (en) METHOD FOR THE TREATMENT OF MAMMAL DISEASES AND THE CYVITTERION COMPOSITION
FI982745A (en) TIE-2 receptor ligands (TIE-ligand-3; TIE-ligand-4) and their use "
RU93004535A (en) COMPOUNDS, METHOD OF OBTAINING AND PHARMACEUTICAL COMPOSITION ON THEIR BASIS
JPH04305535A (en) Combination of therapeutic active substances having cell proliferation inhibiting action or cytotoxicic action
RU93054754A (en) 6-HETEROCYCLO-4-AMINO-1,3,4,5-TETRAHYDROBENZ / CD / INDOLS, THEIR APPLICATION FOR THE TREATMENT OF SUSPENSION AND MORPHANIZED PHENOMENA, PHARMACEUTICAL COMPOSITION, THE METHOD OF THEIR
RU2001114528A (en) A receptor body that specifically binds a TIE-2 ligand, an isolated nucleic acid molecule, a plasmid, a pharmaceutical composition, a method for preventing or attenuating neovascularization in a mammal
IT9020020A0 (en) "2-SUBSTITUTED N,N'-DITRIMETHOXYBENZOILPIPERAZINES, PROCEDURE FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS THAT CONTAIN THEM
HU9700661D0 (en) Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer
AR002191A1 (en) ORAL PHARMACEUTICAL COMPOSITION OF PIPERIDINOALCANOL COMPOUNDS IN THE FORM OF SOLUTION, PROCEDURE FOR ITS PREPARATION
CA2290739A1 (en) New bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy
OA07270A (en) N- (vinblastinoyl-23) amino acid derivatives, their preparation and therapeutic application.
CA2257973A1 (en) T cell antigen receptor peptides
AU707158B2 (en) A drug for the treatment of cancer